Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
Bayer said on March 11 that it has filed its oral androgen receptor inhibitor Nubeqa (darolutamide) for an additional indication of prostate cancer with distant metastasis in Japan.In Japan, the drug was approved in January 2020 for the treatment of…
To read the full story
Related Article
BUSINESS
- AstraZeneca’s Etcamah to Hit Japan Market on Nov. 27
November 20, 2026
- J&J’s Icotyde Could Broaden Psoriasis Treatment Options: Expert
November 20, 2026
- Nippon Kayaku to Acquire AstraZeneca’s Zoladex on Dec. 16
November 20, 2026
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026





